JP2004521126A - （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用 - Google Patents
（ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用 Download PDFInfo
- Publication number
- JP2004521126A JP2004521126A JP2002567281A JP2002567281A JP2004521126A JP 2004521126 A JP2004521126 A JP 2004521126A JP 2002567281 A JP2002567281 A JP 2002567281A JP 2002567281 A JP2002567281 A JP 2002567281A JP 2004521126 A JP2004521126 A JP 2004521126A
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- group
- compound
- alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MRTIWTGAGMZREP-QXMHVHEDSA-N [(z)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1\C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-QXMHVHEDSA-N 0.000 title abstract description 13
- 239000003814 drug Substances 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- -1 phosphonato, amino Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000002062 proliferating effect Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000004442 acylamino group Chemical group 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 201000004931 neurofibromatosis Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 208000000571 Fibrocystic breast disease Diseases 0.000 claims 1
- 208000011803 breast fibrocystic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 28
- 125000004429 atom Chemical group 0.000 description 23
- 150000003568 thioethers Chemical class 0.000 description 21
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 20
- 230000001590 oxidative effect Effects 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- WZDKIPVHBCBPCR-QXMHVHEDSA-N [(z)-2-benzylsulfanylethenyl]benzene Chemical compound C=1C=CC=CC=1CS\C=C/C1=CC=CC=C1 WZDKIPVHBCBPCR-QXMHVHEDSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- WNRZZMBEORNQMB-UHFFFAOYSA-N (2-chloro-4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C(Cl)=C1 WNRZZMBEORNQMB-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- HRUJQXRGWQWYDH-UHFFFAOYSA-N 1-ethynyl-2,4-difluorobenzene Chemical group FC1=CC=C(C#C)C(F)=C1 HRUJQXRGWQWYDH-UHFFFAOYSA-N 0.000 description 3
- WMNRKIVJDZUMOE-UHFFFAOYSA-N 4-ethynyl-2-methoxyphenol Chemical group COC1=CC(C#C)=CC=C1O WMNRKIVJDZUMOE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- ZSPXTTVUJDSRNJ-UHFFFAOYSA-N (2,4-dichlorophenyl)methanethiol Chemical compound SCC1=CC=C(Cl)C=C1Cl ZSPXTTVUJDSRNJ-UHFFFAOYSA-N 0.000 description 2
- DVAWWNQISAMREX-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)methanethiol Chemical compound FC1=CC=C(CS)C(Cl)=C1 DVAWWNQISAMREX-UHFFFAOYSA-N 0.000 description 2
- CUCKXDPCCYHFMQ-UHFFFAOYSA-N (4-bromophenyl)methanethiol Chemical compound SCC1=CC=C(Br)C=C1 CUCKXDPCCYHFMQ-UHFFFAOYSA-N 0.000 description 2
- GKQXPTHQTXCXEV-UHFFFAOYSA-N (4-chlorophenyl)methanethiol Chemical compound SCC1=CC=C(Cl)C=C1 GKQXPTHQTXCXEV-UHFFFAOYSA-N 0.000 description 2
- UGPZOWXCYINLLF-UHFFFAOYSA-N (4-ethynyl-2-methoxyphenyl) acetate Chemical group COC1=CC(C#C)=CC=C1OC(C)=O UGPZOWXCYINLLF-UHFFFAOYSA-N 0.000 description 2
- RKTRHMNWVZRZJQ-UHFFFAOYSA-N (4-fluorophenyl)methanethiol Chemical compound FC1=CC=C(CS)C=C1 RKTRHMNWVZRZJQ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZJBQVHITAJZERN-UHFFFAOYSA-N 1,2-dichloro-3-ethynylbenzene Chemical group ClC1=CC=CC(C#C)=C1Cl ZJBQVHITAJZERN-UHFFFAOYSA-N 0.000 description 2
- NFMXTOPFQVKEMY-UHFFFAOYSA-N 1-ethynyl-2,3-dimethylbenzene Chemical group CC1=CC=CC(C#C)=C1C NFMXTOPFQVKEMY-UHFFFAOYSA-N 0.000 description 2
- IVORCBKUUYGUOL-UHFFFAOYSA-N 1-ethynyl-2,4-dimethoxybenzene Chemical group COC1=CC=C(C#C)C(OC)=C1 IVORCBKUUYGUOL-UHFFFAOYSA-N 0.000 description 2
- GMODJHLJRNXLMC-UHFFFAOYSA-N 1-ethynyl-2,4-dimethylbenzene Chemical group CC1=CC=C(C#C)C(C)=C1 GMODJHLJRNXLMC-UHFFFAOYSA-N 0.000 description 2
- RMSZXRRYRZBYTC-UHFFFAOYSA-N 2,4-dichloro-1-ethynylbenzene Chemical group ClC1=CC=C(C#C)C(Cl)=C1 RMSZXRRYRZBYTC-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- YPFVPWQTXAOXBW-UHFFFAOYSA-N Br.Br.C=CC1=CC=CC=C1 Chemical class Br.Br.C=CC1=CC=CC=C1 YPFVPWQTXAOXBW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- OUMRUWRPTBYLRS-UHFFFAOYSA-N phenylmethanethiol;sodium Chemical class [Na].SCC1=CC=CC=C1 OUMRUWRPTBYLRS-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CXXYXDKJRAOBKX-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C(OC)=C1 CXXYXDKJRAOBKX-UHFFFAOYSA-N 0.000 description 1
- JHPCOZJGZURWKB-UHFFFAOYSA-N (2,4-dimethylphenyl)methanethiol Chemical compound CC1=CC=C(CS)C(C)=C1 JHPCOZJGZURWKB-UHFFFAOYSA-N 0.000 description 1
- SKLZTWWBEAOCPB-UHFFFAOYSA-N (2-aminophenyl)methanethiol Chemical compound NC1=CC=CC=C1CS SKLZTWWBEAOCPB-UHFFFAOYSA-N 0.000 description 1
- KFUKQIJXSWCBIA-UHFFFAOYSA-N (2-chloro-4-methylphenyl)methanethiol Chemical compound CC1=CC=C(CS)C(Cl)=C1 KFUKQIJXSWCBIA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- FWYJPCBQOURGOR-UHFFFAOYSA-N (4-ethynylphenyl)phosphonic acid Chemical group OP(O)(=O)C1=CC=C(C#C)C=C1 FWYJPCBQOURGOR-UHFFFAOYSA-N 0.000 description 1
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 1
- AGFYZLVFPSGUIX-UHFFFAOYSA-N (4-methylphenyl)methanethiol Chemical compound CC1=CC=C(CS)C=C1 AGFYZLVFPSGUIX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IAKXFWIVQDSYPD-PVRNWPCDSA-N 1,2-dichloro-3-[(z)-3-(2-chloro-4-fluorophenyl)-3-[(z)-1-(2-chloro-4-fluorophenyl)-3-(2,3-dichlorophenyl)prop-2-enyl]sulfanylprop-1-enyl]benzene Chemical compound ClC1=CC(F)=CC=C1C(\C=C/C=1C(=C(Cl)C=CC=1)Cl)SC(C=1C(=CC(F)=CC=1)Cl)\C=C/C1=CC=CC(Cl)=C1Cl IAKXFWIVQDSYPD-PVRNWPCDSA-N 0.000 description 1
- WAPBEQWCSKYAGR-WHYMJUELSA-N 1-[(z)-3-(4-bromophenyl)-3-[(z)-1-(4-bromophenyl)-3-(2,3-dichlorophenyl)prop-2-enyl]sulfanylprop-1-enyl]-2,3-dichlorobenzene Chemical compound ClC1=CC=CC(\C=C/C(SC(\C=C/C=2C(=C(Cl)C=CC=2)Cl)C=2C=CC(Br)=CC=2)C=2C=CC(Br)=CC=2)=C1Cl WAPBEQWCSKYAGR-WHYMJUELSA-N 0.000 description 1
- TUJOQSJQFRDWHX-DUGOVBPYSA-N 1-[(z)-3-(4-chlorophenyl)-3-[(z)-1-(4-chlorophenyl)-3-(2,4-difluorophenyl)prop-2-enyl]sulfanylprop-1-enyl]-2,4-difluorobenzene Chemical compound FC1=CC(F)=CC=C1\C=C/C(C=1C=CC(Cl)=CC=1)SC(C=1C=CC(Cl)=CC=1)\C=C/C1=CC=C(F)C=C1F TUJOQSJQFRDWHX-DUGOVBPYSA-N 0.000 description 1
- ALEKDQZTNXPPJA-AXPXABNXSA-N 1-[(z)-3-(4-chlorophenyl)-3-[(z)-1-(4-chlorophenyl)-3-(2,4-dimethylphenyl)prop-2-enyl]sulfanylprop-1-enyl]-2,4-dimethylbenzene Chemical compound CC1=CC(C)=CC=C1\C=C/C(C=1C=CC(Cl)=CC=1)SC(C=1C=CC(Cl)=CC=1)\C=C/C1=CC=C(C)C=C1C ALEKDQZTNXPPJA-AXPXABNXSA-N 0.000 description 1
- MELOGFKBWVNCMO-YZLQMOBTSA-N 1-[(z)-3-[(z)-3-(2,4-dimethoxyphenyl)-1-(4-fluorophenyl)prop-2-enyl]sulfanyl-3-(4-fluorophenyl)prop-1-enyl]-2,4-dimethoxybenzene Chemical compound COC1=CC(OC)=CC=C1\C=C/C(C=1C=CC(F)=CC=1)SC(C=1C=CC(F)=CC=1)\C=C/C1=CC=C(OC)C=C1OC MELOGFKBWVNCMO-YZLQMOBTSA-N 0.000 description 1
- VSINARGSOQLHQP-PVRNWPCDSA-N 2,4-dichloro-1-[(z)-3-(2-chloro-4-methylphenyl)-3-[(z)-1-(2-chloro-4-methylphenyl)-3-(2,4-dichlorophenyl)prop-2-enyl]sulfanylprop-1-enyl]benzene Chemical compound ClC1=CC(C)=CC=C1C(\C=C/C=1C(=CC(Cl)=CC=1)Cl)SC(C=1C(=CC(C)=CC=1)Cl)\C=C/C1=CC=C(Cl)C=C1Cl VSINARGSOQLHQP-PVRNWPCDSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FBQUBLQMBSKVOS-NFLUSIDLSA-N 2-[(z)-1-[(z)-1-(2-aminophenyl)-3-(2,4-difluorophenyl)prop-2-enyl]sulfanyl-3-(2,4-difluorophenyl)prop-2-enyl]aniline Chemical compound NC1=CC=CC=C1C(\C=C/C=1C(=CC(F)=CC=1)F)SC(C=1C(=CC=CC=1)N)\C=C/C1=CC=C(F)C=C1F FBQUBLQMBSKVOS-NFLUSIDLSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- UGIIACGASYCKOR-UHFFFAOYSA-N 3-benzylthiophene-2-carboxylic acid Chemical class S1C=CC(CC=2C=CC=CC=2)=C1C(=O)O UGIIACGASYCKOR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- COSGPULKSHWOGI-GFIWHYBVSA-N 4-[(z)-3-(2-chloro-4-fluorophenyl)-3-[(z)-1-(2-chloro-4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enyl]sulfanylprop-1-enyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(\C=C/C(SC(\C=C/C=2C=C(OC)C(O)=CC=2)C=2C(=CC(F)=CC=2)Cl)C=2C(=CC(F)=CC=2)Cl)=C1 COSGPULKSHWOGI-GFIWHYBVSA-N 0.000 description 1
- PLDATVUQHCMQDI-DWVBSFERSA-N 4-[(z)-3-[(z)-3-(4-hydroxy-3-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfanyl-3-(4-methoxyphenyl)prop-1-enyl]-2-methoxyphenol Chemical compound C1=CC(OC)=CC=C1C(\C=C/C=1C=C(OC)C(O)=CC=1)SC(C=1C=CC(OC)=CC=1)\C=C/C1=CC=C(O)C(OC)=C1 PLDATVUQHCMQDI-DWVBSFERSA-N 0.000 description 1
- KRXDZCLYPQQIHB-YZLQMOBTSA-N 4-[(z)-3-[(z)-3-(4-hydroxy-3-methoxyphenyl)-1-(4-methylphenyl)prop-2-enyl]sulfanyl-3-(4-methylphenyl)prop-1-enyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(\C=C/C(SC(\C=C/C=2C=C(OC)C(O)=CC=2)C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=C1 KRXDZCLYPQQIHB-YZLQMOBTSA-N 0.000 description 1
- WKSQMKBWJAFJQR-UHFFFAOYSA-N 4-ethynylbenzene-1,2-diol Chemical group OC1=CC=C(C#C)C=C1O WKSQMKBWJAFJQR-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- LACIRAAPMZPMHC-UHFFFAOYSA-N CC1=C(C=C/C(C2=C(C=C(C=C2)C)C)S(=O)(=O)C(C2=C(C=C(C=C2)C)C)C=C/C2=C(C=C(C=C2)C)C)C=CC(=C1)C Chemical compound CC1=C(C=C/C(C2=C(C=C(C=C2)C)C)S(=O)(=O)C(C2=C(C=C(C=C2)C)C)C=C/C2=C(C=C(C=C2)C)C)C=CC(=C1)C LACIRAAPMZPMHC-UHFFFAOYSA-N 0.000 description 1
- JCVOPRONQZMLCS-UHFFFAOYSA-N CC1=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=C(C(=CC=C2)C)C)C=CC=C1C Chemical compound CC1=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=C(C(=CC=C2)C)C)C=CC=C1C JCVOPRONQZMLCS-UHFFFAOYSA-N 0.000 description 1
- RDTLNNRHLIZTCB-UHFFFAOYSA-N CC1=C(C=C/C(C2=CC=C(C=C2)Br)S(=O)(=O)C(C2=CC=C(C=C2)Br)C=C/C2=C(C(=CC=C2)C)C)C=CC=C1C Chemical compound CC1=C(C=C/C(C2=CC=C(C=C2)Br)S(=O)(=O)C(C2=CC=C(C=C2)Br)C=C/C2=C(C(=CC=C2)C)C)C=CC=C1C RDTLNNRHLIZTCB-UHFFFAOYSA-N 0.000 description 1
- FXHOOIQNYSKOCS-UHFFFAOYSA-N CC1=C(C=C/C(C2=CC=C(C=C2)Cl)S(=O)(=O)C(C2=CC=C(C=C2)Cl)C=C/C2=C(C=C(C=C2)C)C)C=CC(=C1)C Chemical compound CC1=C(C=C/C(C2=CC=C(C=C2)Cl)S(=O)(=O)C(C2=CC=C(C=C2)Cl)C=C/C2=C(C=C(C=C2)C)C)C=CC(=C1)C FXHOOIQNYSKOCS-UHFFFAOYSA-N 0.000 description 1
- OQMXTHCNMQEVPB-UHFFFAOYSA-N COC1=C(C=C/C(C2=C(C=C(C=C2)OC)OC)S(=O)(=O)C(C2=C(C=C(C=C2)OC)OC)C=C/C2=C(C=C(C=C2)OC)OC)C=CC(=C1)OC Chemical compound COC1=C(C=C/C(C2=C(C=C(C=C2)OC)OC)S(=O)(=O)C(C2=C(C=C(C=C2)OC)OC)C=C/C2=C(C=C(C=C2)OC)OC)C=CC(=C1)OC OQMXTHCNMQEVPB-UHFFFAOYSA-N 0.000 description 1
- UDRVFCLDMZGUSA-UHFFFAOYSA-N COC1=C(C=C/C(C2=CC=C(C=C2)F)S(=O)(=O)C(C2=CC=C(C=C2)F)C=C/C2=C(C=C(C=C2)OC)OC)C=CC(=C1)OC Chemical compound COC1=C(C=C/C(C2=CC=C(C=C2)F)S(=O)(=O)C(C2=CC=C(C=C2)F)C=C/C2=C(C=C(C=C2)OC)OC)C=CC(=C1)OC UDRVFCLDMZGUSA-UHFFFAOYSA-N 0.000 description 1
- VCKYJKGFINXAAQ-MZAUSLISSA-N COC1=CC(Cl)=C(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)S(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)C(C=CC(OC)=C2)=C2Cl)(=O)=O)C=C1 Chemical compound COC1=CC(Cl)=C(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)S(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)C(C=CC(OC)=C2)=C2Cl)(=O)=O)C=C1 VCKYJKGFINXAAQ-MZAUSLISSA-N 0.000 description 1
- WWOGCPFUUXWGIZ-MZAUSLISSA-N COC1=CC(Cl)=C(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)SC(/C=C\C(C=C2)=CC=C2P(O)(O)=O)C(C=CC(OC)=C2)=C2Cl)C=C1 Chemical compound COC1=CC(Cl)=C(C(/C=C\C(C=C2)=CC=C2P(O)(O)=O)SC(/C=C\C(C=C2)=CC=C2P(O)(O)=O)C(C=CC(OC)=C2)=C2Cl)C=C1 WWOGCPFUUXWGIZ-MZAUSLISSA-N 0.000 description 1
- YQMICQYXIOEWPB-UHFFFAOYSA-N COC=1C=C(C=C/C(C2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)Cl)Cl)C=C/C2=CC(=C(C=C2)OC(C)=O)OC)C=CC1OC(C)=O Chemical compound COC=1C=C(C=C/C(C2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)Cl)Cl)C=C/C2=CC(=C(C=C2)OC(C)=O)OC)C=CC1OC(C)=O YQMICQYXIOEWPB-UHFFFAOYSA-N 0.000 description 1
- MVRMCXOJQYMXRP-UHFFFAOYSA-N COC=1C=C(C=C/C(C2=C(C=C(C=C2)F)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)F)Cl)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O Chemical compound COC=1C=C(C=C/C(C2=C(C=C(C=C2)F)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)F)Cl)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O MVRMCXOJQYMXRP-UHFFFAOYSA-N 0.000 description 1
- ROSWFOQVCPGGSG-UHFFFAOYSA-N COC=1C=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=CC(=C(C=C2)OC(C)=O)OC)C=CC1OC(C)=O Chemical compound COC=1C=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=CC(=C(C=C2)OC(C)=O)OC)C=CC1OC(C)=O ROSWFOQVCPGGSG-UHFFFAOYSA-N 0.000 description 1
- TWLWSGBYVYVCGQ-UHFFFAOYSA-N COC=1C=C(C=C/C(C2=CC=C(C=C2)C)S(=O)(=O)C(C2=CC=C(C=C2)C)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O Chemical compound COC=1C=C(C=C/C(C2=CC=C(C=C2)C)S(=O)(=O)C(C2=CC=C(C=C2)C)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O TWLWSGBYVYVCGQ-UHFFFAOYSA-N 0.000 description 1
- CTDPDNOVEOVNSL-UHFFFAOYSA-N COC=1C=C(C=C/C(C2=CC=C(C=C2)OC)S(=O)(=O)C(C2=CC=C(C=C2)OC)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O Chemical compound COC=1C=C(C=C/C(C2=CC=C(C=C2)OC)S(=O)(=O)C(C2=CC=C(C=C2)OC)C=C/C2=CC(=C(C=C2)O)OC)C=CC1O CTDPDNOVEOVNSL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- JZGOTNNDGDVMRO-UHFFFAOYSA-N ClC1=C(C=C/C(C2=C(C=C(C=C2)C)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)C)Cl)C=C/C2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl Chemical compound ClC1=C(C=C/C(C2=C(C=C(C=C2)C)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)C)Cl)C=C/C2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl JZGOTNNDGDVMRO-UHFFFAOYSA-N 0.000 description 1
- ZZEQNAAVXGJKMF-UHFFFAOYSA-N ClC1=C(C=C/C(C2=C(C=C(C=C2)F)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)F)Cl)C=C/C2=C(C(=CC=C2)Cl)Cl)C=CC=C1Cl Chemical compound ClC1=C(C=C/C(C2=C(C=C(C=C2)F)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)F)Cl)C=C/C2=C(C(=CC=C2)Cl)Cl)C=CC=C1Cl ZZEQNAAVXGJKMF-UHFFFAOYSA-N 0.000 description 1
- AINNDIMRMZMRRM-UHFFFAOYSA-N ClC1=C(C=C/C(C2=CC=C(C=C2)F)S(=O)(=O)C(C2=CC=C(C=C2)F)C=C/C2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl Chemical compound ClC1=C(C=C/C(C2=CC=C(C=C2)F)S(=O)(=O)C(C2=CC=C(C=C2)F)C=C/C2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl AINNDIMRMZMRRM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- NQOOCLCWZQWSCK-UHFFFAOYSA-N FC1=C(C=C/C(C2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)Cl)Cl)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F Chemical compound FC1=C(C=C/C(C2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)Cl)Cl)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F NQOOCLCWZQWSCK-UHFFFAOYSA-N 0.000 description 1
- ZIYUTAKKRLSUIB-UHFFFAOYSA-N FC1=C(C=C/C(C2=C(C=CC=C2)N)S(=O)(=O)C(C2=C(C=CC=C2)N)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F Chemical compound FC1=C(C=C/C(C2=C(C=CC=C2)N)S(=O)(=O)C(C2=C(C=CC=C2)N)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F ZIYUTAKKRLSUIB-UHFFFAOYSA-N 0.000 description 1
- VPGMURFDVKBUDH-UHFFFAOYSA-N FC1=C(C=C/C(C2=CC=C(C=C2)Cl)S(=O)(=O)C(C2=CC=C(C=C2)Cl)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F Chemical compound FC1=C(C=C/C(C2=CC=C(C=C2)Cl)S(=O)(=O)C(C2=CC=C(C=C2)Cl)C=C/C2=C(C=C(C=C2)F)F)C=CC(=C1)F VPGMURFDVKBUDH-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WAXSKXOIRYUNDC-UHFFFAOYSA-N OC=1C=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=CC(=C(C=C2)O)O)C=CC1O Chemical compound OC=1C=C(C=C/C(C2=C(C=C(C=C2)OC)Cl)S(=O)(=O)C(C2=C(C=C(C=C2)OC)Cl)C=C/C2=CC(=C(C=C2)O)O)C=CC1O WAXSKXOIRYUNDC-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UMUSKHPCADBQQY-DUGOVBPYSA-N [4-[(z)-3-[(z)-3-(4-acetyloxy-3-methoxyphenyl)-1-(2,4-dichlorophenyl)prop-2-enyl]sulfanyl-3-(2,4-dichlorophenyl)prop-1-enyl]-2-methoxyphenyl] acetate Chemical compound C1=C(OC(C)=O)C(OC)=CC(\C=C/C(SC(\C=C/C=2C=C(OC)C(OC(C)=O)=CC=2)C=2C(=CC(Cl)=CC=2)Cl)C=2C(=CC(Cl)=CC=2)Cl)=C1 UMUSKHPCADBQQY-DUGOVBPYSA-N 0.000 description 1
- ABBPQMXOFAOXNZ-XFQWXJFMSA-N [4-[(z)-3-[(z)-3-(4-acetyloxy-3-methoxyphenyl)-1-(2-chloro-4-methoxyphenyl)prop-2-enyl]sulfanyl-3-(2-chloro-4-methoxyphenyl)prop-1-enyl]-2-methoxyphenyl] acetate Chemical compound ClC1=CC(OC)=CC=C1C(\C=C/C=1C=C(OC)C(OC(C)=O)=CC=1)SC(C=1C(=CC(OC)=CC=1)Cl)\C=C/C1=CC=C(OC(C)=O)C(OC)=C1 ABBPQMXOFAOXNZ-XFQWXJFMSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- PMOWTIHVNWZYFI-WAYWQWQTSA-N cis-2-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1O PMOWTIHVNWZYFI-WAYWQWQTSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000020071 rectified spirit Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SNCHEDBJOUWPMJ-UHFFFAOYSA-M sodium;phenylmethanethiolate Chemical class [Na+].[S-]CC1=CC=CC=C1 SNCHEDBJOUWPMJ-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27176201P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/005817 WO2002067913A1 (en) | 2001-02-27 | 2002-02-26 | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521126A true JP2004521126A (ja) | 2004-07-15 |
| JP2004521126A5 JP2004521126A5 (https=) | 2005-12-22 |
Family
ID=23036961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567281A Pending JP2004521126A (ja) | 2001-02-27 | 2002-02-26 | （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6833480B2 (https=) |
| EP (1) | EP1379228A4 (https=) |
| JP (1) | JP2004521126A (https=) |
| CA (1) | CA2439256A1 (https=) |
| WO (1) | WO2002067913A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513877A (ja) * | 2003-11-14 | 2007-05-31 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα，β−不飽和スルホキシド |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| NZ535232A (en) * | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| NZ549962A (en) | 2004-03-16 | 2010-04-30 | Univ Temple | Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders |
| US8058313B2 (en) | 2004-06-24 | 2011-11-15 | Temple University—Of the Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| GB0604233D0 (en) * | 2006-03-02 | 2006-04-12 | Syngenta Participations Ag | Process |
| US8735620B2 (en) | 2008-12-17 | 2014-05-27 | Epr Pharmaceuticals Pvt. Ltd | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders |
| AU2013318206B2 (en) | 2012-09-20 | 2018-07-26 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| WO2014089483A1 (en) | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
| US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532612A (en) | 1945-08-29 | 1950-12-05 | Union Oil Co | Preparation of unsaturated thio-ethers |
| US3185743A (en) | 1960-08-24 | 1965-05-25 | Union Carbide Corp | Production of olefinic compounds from allyl sulfones |
| US3463774A (en) | 1963-03-18 | 1969-08-26 | Hoffmann La Roche | Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines |
| US3418101A (en) | 1965-12-15 | 1968-12-24 | Pennsalt Chemicals Corp | Process for plant desiccation |
| US3514386A (en) | 1967-12-11 | 1970-05-26 | Exxon Research Engineering Co | Stereoselective addition of thiols to acetylenic compounds |
| US3917714A (en) | 1972-09-06 | 1975-11-04 | American Cyanamid Co | Bis(alkylsulfonyl)vinylbenzenes |
| US4161407A (en) | 1977-10-06 | 1979-07-17 | Eastman Kodak Company | Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin |
| US4386221A (en) | 1981-10-28 | 1983-05-31 | Eastman Kodak Company | Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones |
| US4937388A (en) | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| US5659087A (en) | 1995-06-07 | 1997-08-19 | Eli Lilly And Company | Diarylvinyl sulfoxides |
| US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
| CN1163480C (zh) * | 1997-10-03 | 2004-08-25 | 坦普尔大学 | 苯乙烯砜抗癌剂 |
| US6201154B1 (en) | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| JP4596651B2 (ja) | 1999-04-02 | 2010-12-08 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | （ｅ）−スチリルスルホン抗癌剤 |
| US6185743B1 (en) * | 1999-06-10 | 2001-02-13 | John D. Mick | Beach toga with partial belt |
| US6418101B1 (en) * | 1999-09-03 | 2002-07-09 | Zen Research (Ireland), Ltd. | Digital read channel for optical disk reader |
| WO2001026645A1 (en) | 1999-10-12 | 2001-04-19 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
-
2002
- 2002-02-26 JP JP2002567281A patent/JP2004521126A/ja active Pending
- 2002-02-26 US US10/469,056 patent/US6833480B2/en not_active Expired - Lifetime
- 2002-02-26 CA CA002439256A patent/CA2439256A1/en not_active Abandoned
- 2002-02-26 WO PCT/US2002/005817 patent/WO2002067913A1/en not_active Ceased
- 2002-02-26 EP EP02714999A patent/EP1379228A4/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513877A (ja) * | 2003-11-14 | 2007-05-31 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα，β−不飽和スルホキシド |
Also Published As
| Publication number | Publication date |
|---|---|
| US6833480B2 (en) | 2004-12-21 |
| CA2439256A1 (en) | 2002-09-06 |
| WO2002067913A8 (en) | 2002-11-14 |
| US20040133030A1 (en) | 2004-07-08 |
| EP1379228A4 (en) | 2006-01-04 |
| EP1379228A1 (en) | 2004-01-14 |
| WO2002067913A1 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100655808B1 (ko) | 혈관 손상제로서 콜치놀 유도체, 그것의 용도 및 제조 방법 | |
| CN116891487A (zh) | 作为kras g12d抑制剂的杂环化合物 | |
| KR100768415B1 (ko) | 치환된 스티릴 벤질설폰, 이의 제조방법 및 이를 포함하는 증식성 장애 치료용 약제학적 조성물 | |
| ES2551086T3 (es) | Análogos de combretastatina con actividad de unión a tubulina | |
| JP2004521126A (ja) | （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用 | |
| WO2017000379A1 (zh) | 酞菁硅配合物、其制备方法及其在医药上的应用 | |
| CA2379544A1 (en) | New stilbenes with vascular damaging activity | |
| JP4162994B2 (ja) | 諸疾患状態の処置のための薬物に使用する化合物とその製造方法 | |
| JP4780885B2 (ja) | 正常細胞を化学療法剤の細胞毒性から保護するための方法 | |
| AU2018403404A2 (en) | Compound and use thereof in medicine | |
| EP3296294B1 (en) | Compound for treating or preventing breast cancer | |
| US10383831B2 (en) | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use | |
| JP2004510761A (ja) | 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン | |
| HUE025949T2 (en) | Salts of isophosphoramide mustard and analogues thereof | |
| EP0129258A1 (en) | Imidazoquinazoline compound | |
| HUP0102932A2 (hu) | Bioreduktív citotoxikus ágensek | |
| JP2005507424A (ja) | 固形腫瘍の処置における７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の使用 | |
| AU2011274194B2 (en) | Phenyl nitrone compounds containing stilbene segment and use thereof | |
| US7405309B2 (en) | Pyranone derivatives useful for treating cancer | |
| WO2016079522A1 (en) | Androgen receptor modulators and their use as anti-cancer agents | |
| US6020379A (en) | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia | |
| CA2646874C (en) | Processes for preparing (e)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | |
| WO2019152955A9 (en) | Small molecule drug conjugates of gemcitabine monophosphate | |
| JPS59101471A (ja) | 放射線療法の補助薬として有用な３−ニトロピラジンの２，６−ジ置換誘導体 | |
| ES2686733T3 (es) | Derivados de 4-oxo-N-(4-hidroxifenil)retinamida como agentes terapéuticos para el tratamiento de cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080501 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080501 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080501 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081014 |